This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga_article·5 hours agoHRB+6.77%FTH-0.48%
Benitec Biopharma Limited (NASDAQ:BNTC) Given Average Recommendation of "Moderate Buy" by AnalystsMarket Beat·12 hours agoBNTC+3.45%BAC+0.44%
Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD DysphagiaTip Ranks·May 14 at 09:55 PMBNTC+3.45%
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors | BNTC Stock NewsStockTitan·Apr 26 at 10:05 PMITCI0.00%PRTC0.00%
Benitec Biopharma's (BNTC) "Buy" Rating Reaffirmed at HC WainwrightMarket Beat·Mar 9 at 11:50 AMBNTC+3.45%
Benitec Biopharma shares are trading higher after the company announced Oculopharyngeal Muscular Dystrophy Patients treated with BB-301 experienced improvements in throat closure, throat emptying, and total dysphagic symptom burden.benzinga_article·Mar 9 at 11:33 AMBNTC+3.45%
Benitec Biopharma (NASDAQ:BNTC) Shares Cross Below 50-Day Moving Average - Here's WhyMarket Beat·Feb 25 at 05:35 AMBNTC+3.45%
